FCN-411

Dizal's JAK1 inhibitor golidocitinib combined with PD-1 antibodies achieved a 44.3% objective response rate in non-small cell lung cancer patients who progressed on prior anti-PD-1 therapy.

Akeso has completed enrollment for the HARMONi-6 Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy for first-line squamous non-small cell lung cancer treatment.

CSPC Pharmaceutical's SYS6010 receives Breakthrough Therapy Designation from China's NMPA for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yuhan Corporation's third-generation EGFR-TKI lazertinib (Leclaza) has received European Commission approval in combination with J&J's Rybrevant for first-line treatment of EGFR-mutated non-small cell lung cancer.

AstraZeneca's Tagrisso (osimertinib) gains EU approval for treating unresectable EGFR-mutated non-small cell lung cancer (NSCLC) in adults after platinum-based chemoradiation therapy.